1. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial 
Prof Luis Rivera, MD, Rasmus S Pedersen, PhD, Lourdes Peña, MD, Klaus J Olsen, PhD, Lars V Andreasen, PhD, Ingrid Kromann, BSc, Pernille I Nielsen, MSc, Charlotte Sørensen, MSc, Jes Dietrich, PhD, Ananda S Bandyopadhyay, MBBS, Birgit Thierry-Carstensen, MSc 
The Lancet Infectious Diseases 
Volume 17, Issue 7, Pages (July 2017)
DOI: /S (17)
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

2. Figure
Trial profile
All vaccines were manufactured by SSI. FAS=full analysis set. IPV=inactivated polio vaccine. IPV-Al=IPV adsorbed to aluminium hydroxide. PP=per-protocol.
The Lancet Infectious Diseases  , DOI: ( /S (17) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions